Sangamo Therapeutics (SGMO) experienced a decline today, closing at $2.39, down 3.24% from the previous close of $2.47. The stock opened at $2.34, reached a high of $2.59, and a low of $2.34, with trading volume at 5,852,188 shares, which is 69.99% of its average volume. Despite the recent positive news of a licensing agreement with Astellas Pharma, which includes a $20 million upfront payment and potential for up to $1.3 billion in additional fees and milestone payments, the stock gapped down at the open. This decline may be attributed to broader market conditions or profit-taking following the initial positive reaction to the Astellas deal. Analysts have been optimistic, with several upgrading their ratings and increasing price targets, yet the stock faced downward pressure today.